Spartan Bioscience Appoints Roger Eacock as Chief Executive Officer, Broadens Executive Team and Welcomes New Board Members

November 10th, 2020

Spartan Bioscience is pleased to announce a strengthened executive leadership team and new members of the Board of Directors. These significant additions position Spartan for the next phase of the company’s growth and include a new Chief Executive Officer...

Read more

Spartan Bioscience Receives Investigational Testing Authorization (ITA) from Health Canada

October 29th, 2020

Spartan Bioscience is pleased to announce we have received Investigational Testing Authorization (ITA) from Health Canada for our COVID-19 testing system. ITA allows Spartan to begin its clinical validation studies on symptomatic patients in Canada. These...

Read more

Spartan Submits COVID-19 Testing System to Health Canada for Investigational Testing Authorization (ITA)

September 21st, 2020

Spartan Bioscience has commenced the regulatory process of its revised COVID-19 point-of-care test and submitted an Investigational Testing Authorization (ITA) application to Health Canada for its review and approval. Upon approval, Spartan will commence...

Read more

Spartan Concludes Covid-19 Test Fix; Prepares for Re-Submission to Health Canada

August 13th, 2020

Spartan Bioscience has developed a fix to our COVID-19 test and is preparing for re-submission to Health Canada. The delay has allowed us to incorporate the latest information on COVID-19 and conclude 12 weeks of intense work where we tested approximately...

Read more

Spartan Bioscience Expands Executive Team

June 12th, 2020

Ottawa-Spartan Bioscience is pleased to announce the expansion of its executive team to provide critical leadership for the company’s recent rapid growth, as well as its focus on supporting Canada’s response to COVID-19. Patrick (Pat) J. Mallon, a member...

Read more